Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026; Favorable claim construction ruling in Pfizer-BioNTech litigation issued in September 2025 Additional ana
(Financial Post, 2025-11-13T12:33:15Z)